Intellia Therapeutics (Intellia Therapeutics) Debt-to-EBITDA : -0.21 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Intellia Therapeutics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Intellia Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $18.60 Mil. Intellia Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $96.75 Mil. Intellia Therapeutics's annualized EBITDA for the quarter that ended in Dec. 2023 was $-549.70 Mil. Intellia Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.21.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Intellia Therapeutics's Debt-to-EBITDA or its related term are showing as below:

NTLA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.3 Med: -0.28 Max: -0.18
Current: -0.23

During the past 10 years, the highest Debt-to-EBITDA Ratio of Intellia Therapeutics was -0.18. The lowest was -0.30. And the median was -0.28.

NTLA's Debt-to-EBITDA is ranked worse than
100% of 278 companies
in the Biotechnology industry
Industry Median: 1.355 vs NTLA: -0.23

Intellia Therapeutics Debt-to-EBITDA Historical Data

The historical data trend for Intellia Therapeutics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intellia Therapeutics Debt-to-EBITDA Chart

Intellia Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.18

-0.30

-0.28

-0.29

-0.23

Intellia Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.30	-0.29	-0.24	-0.23	-0.21

Competitive Comparison of Intellia Therapeutics's Debt-to-EBITDA

For the Biotechnology subindustry, Intellia Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intellia Therapeutics's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Intellia Therapeutics's Debt-to-EBITDA falls into.

Intellia Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Intellia Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(18.599	+	96.747)	/	-506.315
	=	-0.23

Intellia Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(18.599	+	96.747)	/	-549.704
	=	-0.21

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Intellia Therapeutics (NAS:NTLA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Intellia Therapeutics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Intellia Therapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Intellia Therapeutics (Intellia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intellia Therapeutics Inc (NAS:NTLA) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

38I:Germany

Address

40 Erie Street, Suite 130, Cambridge, MA, USA, 02139

Website

https://www.intelliatx.com

Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Executives

Laura Sepp-lorenzino	officer: EVP, Chief Scientific Officer	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
James Basta	officer: EVP, General Counsel	C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK RD, SUITE 220, SAN DIEGO CA 92121
Derek Hicks	officer: EVP, Chief Business Officer	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET SUITE 130, CAMBRIDGE MA 02139
Eliana Clark	officer: EVP, Chief Technical Officer	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
David Lebwohl	officer: EVP, Chief Medical Officer	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Glenn Goddard	officer: See Remarks	C/O INTELLIA THERAPEUTICS, INC, 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
John M. Leonard	director, officer: President and CEO	C/O INTELLIA THERAPEUTICS INC, 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Muna Bhanji	director	C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
William J Chase	director	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
John F Crowley	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Georgia Keresty	director	C/O ASPEN TECHNOLOGY, INC., 20 CROSBY DRIVE, BEDFORD MA 01730
Jean Francois Formela	director	C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451
Caroline Dorsa	director	BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Jose E Rivera	officer: EVP, General Counsel	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE MA 02139
Andrew Schiermeier	officer: EVP, Chief Operating Officer	C/O INTELLIA THERAPEUTICS, INC, 40 ERIE STREET STE 130, CAMBRIDGE MA 02139